Phenotypes associated with this allele

• Allele Symbol: Pilrb1^tm1Pgh
• Allele Name: targeted mutation 1, Paul G Heyworth
• Allele ID: MGI:4437413
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Pilrb1^tm1Pgh/Pilrb1^tm1Pgh	involves: C57BL/6	MGI:4437414

Genotype
MGI:4437414

hm1

• Allelic Composition: Pilrb1^tm1Pgh/Pilrb1^tm1Pgh
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased susceptibility to bacterial infection induced morbidity/mortality ( J:157763 )

• following S. aureus infection

immune system

abnormal cytokine level ( J:157763 )

increased circulating interferon-gamma level ( J:157763 )

• following S. aureus infection

decreased circulating interleukin-1 beta level ( J:157763 )

• following S. aureus infection

increased circulating interleukin-12 level ( J:157763 )

• following S. aureus infection

decreased circulating interleukin-6 level ( J:157763 )

• following S. aureus infection

decreased circulating tumor necrosis factor level ( J:157763 )

• following S. aureus infection

abnormal chemokine level ( J:157763 )

• following S. aureus infection, serum levels of MCP-1 are increased compared to in similarly treated wild-type mice

• following S. aureus infection, bronchoalveolar lavage fluid levels of KC are increased compared to in similarly treated wild-type mice

• macrophages exposed to S. aureus produce 2- to 6-fold more KC compared with similarly treated wild-type cells

abnormal cytokine secretion ( J:157763 )

increased interferon-gamma secretion ( J:157763 )

• following S. aureus infection, bronchoalveolar lavage fluid levels of IFN-gamma are increased compared to in similarly treated wild-type mice

• macrophages exposed to S. aureus produce 2- to 6-fold more IFN-gamma compared with similarly treated wild-type cells

decreased interleukin-1 beta secretion ( J:157763 )

• following S. aureus infection, bronchoalveolar fluid levels of IL1b are reduced compared to in similarly treated wild-type mice

• macrophages exposed to S. aureus produce 2- to 3-fold less ILb compared with similarly treated wild-type cells

increased interleukin-10 secretion ( J:157763 )

• following S. aureus infection, bronchoalveolar lavage fluid levels of IL10 are increased compared to in similarly treated wild-type mice

increased interleukin-12 secretion ( J:157763 )

• macrophages exposed to S. aureus produce 2- to 6-fold more IL12 compared with similarly treated wild-type cells

decreased tumor necrosis factor secretion ( J:157763 )

• macrophages exposed to S. aureus produce 2- to 3-fold less TNF-alpha compared with similarly treated wild-type cells

decreased susceptibility to bacterial infection ( J:157763 )

• mice exhibit increased resistance to S. aureus infection compared with similarly treated wild-type mice with improved bacterial clearance; lower serum levels of IL1b, IL6, TNF-alpha, and MCP-1; higher serum levels of IFN-gamma and IL12; lower bronchoalveolar lavage levels of IL1b, TNF-alpha; higher broncholavage fluid levels of IFN-gamma, KC, and IL10; and reduced mortality compare with similarly treated wild-type mice

• S. aureus infected macrophages produce 2- to 3-fold less TNF-alpha and IL1b and 2- to 6-fold more IFN-gamma, IL12, and KC compared with similarly treated wild-type cells

• however, neutrophil recruitment into the bronchoalveolar space following S. aureus infection

decreased susceptibility to bacterial infection induced morbidity/mortality ( J:157763 )

• following S. aureus infection

homeostasis/metabolism

abnormal cytokine level ( J:157763 )

increased circulating interferon-gamma level ( J:157763 )

• following S. aureus infection

decreased circulating interleukin-1 beta level ( J:157763 )

• following S. aureus infection

increased circulating interleukin-12 level ( J:157763 )

• following S. aureus infection

decreased circulating interleukin-6 level ( J:157763 )

• following S. aureus infection

decreased circulating tumor necrosis factor level ( J:157763 )

• following S. aureus infection

abnormal chemokine level ( J:157763 )

• following S. aureus infection, serum levels of MCP-1 are increased compared to in similarly treated wild-type mice

• following S. aureus infection, bronchoalveolar lavage fluid levels of KC are increased compared to in similarly treated wild-type mice

• macrophages exposed to S. aureus produce 2- to 6-fold more KC compared with similarly treated wild-type cells